Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lacticaseibacillus rhamnosus BMX 54
- Development stage
- Unknown
- Lead developer
- Polichem
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
**Lacticaseibacillus rhamnosus BMX 54** is a defined live probiotic bacterial strain administered intravaginally to restore or maintain a lactobacillus-predominant vaginal microbiota. It is marketed by Laboratori Baldacci as **Normogin**, a vaginal-tablet product containing lyophilized BMX 54; published studies have evaluated prolonged vaginal use after standard antimicrobial therapy for bacterial vaginosis, vaginitis with concomitant human papillomavirus infection, and prevention of abnormal vaginal flora during pregnancy. Its therapeutic rationale is microbiome restoration rather than direct antimicrobial killing: re-establishment of vaginal eubiosis may lower vaginal pH and impede overgrowth of pathogenic organisms. ([laboratoribaldacci.it](https://laboratoribaldacci.it/aree-terapeutiche/salute-della-donna/normogin/))
- Brand names
- Normogin
- Other names
- BMX 54BMX54BMX-54Lacticaseibacillus rhamnosus BMX 54Lactobacillus rhamnosus BMX 54
Beyond the preview
Go deeper on Lacticaseibacillus rhamnosus BMX 54.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lacticaseibacillus rhamnosus BMX 54.